3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Triple Negative Breast Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Advanced Cancer
1
Interventions
Nivolumab
19
Ipilimumab
9
linrodostat
6
relatlimab
4
Pemetrexed
4
Paclitaxel
4
Carboplatin
4
ARRY-334543
4
Docetaxel
3
regorafenib
2
anlotinib
2
abemaciclib
2
N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide
2
Gemcitabine
2
Cyclophosphamide
2
Capecitabine
2
6-(6-(1-methyl-1H-pyrazol-4-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-ylsulfanyl)quinoline
2
vorolanib
1
trametinib
1
tislelizumab
1
sargramostim
1
ralimetinib
1
prexasertib
1
palifosfamide lysine
1
p38 Mitogen-Activated Protein Kinases
1
mirdametinib
1
lirilumab
1
indibulin
1
gedatolisib
1
fluzoparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Advanced Cancer
×
IDO-1 inhibitor LY3381916
×
Clear all
NCT03335540
2022-09-26
ADVISE
Bristol-Myers Squibb
Phase 1
Completed
20 enrolled